The company has no franking or imputation credits as of their last full year report. Paying a 50c diviend to share holders that isn't franked would be a strange decision when there's an active buyback which is much better for our potential total return.
https://www.neurenpharma.com/pdf/7fa054fc-98c4-4a0a-81fc-c6aac3f42b86/Appendix-4E-and-2023-full-year-accounts.pdf
We don't yet have the 2024 full year report so perhaps they now have the sufficent franking credits but I still maintain that would be an odd decision and all commentary from Jon seems to suggest that a dividend is unlikely.
Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome, page-25
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |